Abstract

Recent advances in proteomic technology reveal G-protein-coupled receptors (GPCRs) are organized as large, macromolecular protein complexes in cell membranes, adding a new layer of intricacy to GPCR signaling. We previously reported the α1D-adrenergic receptor (ADRA1D)—a key regulator of cardiovascular, urinary and CNS function—binds the syntrophin family of PDZ domain proteins (SNTA, SNTB1, and SNTB2) through a C-terminal PDZ ligand interaction, ensuring receptor plasma membrane localization and G-protein coupling. To assess the uniqueness of this novel GPCR complex, 23 human GPCRs containing Type I PDZ ligands were subjected to TAP/MS proteomic analysis. Syntrophins did not interact with any other GPCRs. Unexpectedly, a second PDZ domain protein, scribble (SCRIB), was detected in ADRA1D complexes. Biochemical, proteomic, and dynamic mass redistribution analyses indicate syntrophins and SCRIB compete for the PDZ ligand, simultaneously exist within an ADRA1D multimer, and impart divergent pharmacological properties to the complex. Our results reveal an unprecedented modular dimeric architecture for the ADRA1D in the cell membrane, providing unexpected opportunities for fine-tuning receptor function through novel protein interactions in vivo, and for intervening in signal transduction with small molecules that can stabilize or disrupt unique GPCR:PDZ protein interfaces.

Highlights

  • G-protein-coupled receptors (GPCRs) are a primary target for the development of novel therapeutics to treat disease

  • Interactomes of Type I PDZ ligand GPCRs The uniqueness of the α1D adrenergic (ADRA1D):syntrophin interaction was examined by subjecting 23 Type I PDZ ligand GPCRs to tandem affinity purification followed by mass spectrometry (TAP/MS)

  • None of the GPCRs examined interacted with syntrophins, nor the dystrophin-associated protein complex (DAPC), indicating the ADRA1D:syntrophin complex is unique among Type I PDZ ligand GPCRs

Read more

Summary

Introduction

G-protein-coupled receptors (GPCRs) are a primary target for the development of novel therapeutics to treat disease. PDZ proteins can have robust effects on GPCR cellular localization, signal transduction coupling, ligand binding, and duration of action [4]. Designing small molecules that alter a GPCR:PDZ protein interface may permit precise modulation of specific GPCR signaling pathways, while limiting unwanted side effects, more so if a GPCR:PDZ protein interaction is unique and cell-type specific. Before this intriguing new field of pharmacology can be harvested, GPCR:PDZ protein interactions must be thoroughly characterized

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.